Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 8/20 | 0.44 |
| ▸ | CD274 | Q9NZQ7 | 8/20 | 0.44 |
| ▸ | PNMT | P11086 | 2/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.38 |
| ▸ | OGA | O60502 | 3/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6765448 | 0.98 | PDCD1 (0.43) | PDCD1CD274PNMTTLR9TLR8 | |
| Bromide SCHEMBL3822772 | 0.98 | PDCD1 (0.43) | PDCD1CD274PNMTTLR9TLR8 | |
| SCHEMBL21451979 | 0.89 | PDCD1 (0.36) | PDCD1CD274PNMTTLR9TLR8 | |
| SCHEMBL31143437 | 0.87 | PDCD1 (0.39) | PDCD1CD274PNMTTLR9TLR8 | |
| SCHEMBL6436015 | 0.86 | PDCD1 (0.36) | PDCD1CD274PNMTPDE10A | |
| Bromide SCHEMBL15021264 | 0.84 | PDCD1 (0.35) | PDCD1CD274PNMTPDE10A | |
| SCHEMBL15910247 | 0.84 | PDCD1 (0.48) | PDCD1CD274PNMTTLR9TLR7 | |
| Hydrochloric Acid SCHEMBL7677012 | 0.84 | PDCD1 (0.35) | PDCD1CD274PNMTPDE10A | |
| Hydrochloric Acid SCHEMBL31569096 | 0.82 | PDCD1 (0.47) | PDCD1CD274PNMTTLR9TLR7 | |
| SCHEMBL2846333 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119095839-A | Quinoline derivatives as modulators and related products of Mas-associated G protein receptor X2 | 伊赛恩特制药公司 | 2024-12-06 | — | — | CN | disclosed |
| US-12139498-B1 | Positive allosteric modulators of the muscarinic acetylcholine receptor M4 | VANDERBILT UNIVERSITY (US) | 2024-11-12 | — | — | US | disclosed |
| US-20240368188-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2024-11-07 | — | — | US | disclosed |
| EP-4223369-A1 | IMMUNOMODULATOR COMPOUNDS AND METHODS OF USE | Incyte Corporation (US) | 2023-08-09 | — | — | EP | disclosed |
| US-20230218597-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230218597-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-07-13 | — | — | US | disclosed |
| EP-4190784-A1 | NITROGEN-CONTAINING FUSED RING DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2023-06-07 | — | — | EP | disclosed |
| US-11590116-B2 | Substituted pyridines and methods of use | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-02-28 | — | — | US | disclosed |
| WO-2023023534-A2 | ARYL SULFONYL COMPOUNDS AS CCR6 INHIBITORS | CHEMOCENTRYX, INC. (US) | 2023-02-23 | — | — | WO | disclosed |
| US-20230052191-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2023-02-16 | — | — | US | disclosed |
| EP-1749007-A2 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | Intermune, Inc. (US) | 2007-02-07 | — | — | EP | disclosed |
| EP-1680137-A2 | MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULFONAMIDES AS INHIBITORS OF HCV REPLICATION | Intermune, Inc. (US) | 2006-07-19 | — | — | EP | disclosed |
| US-20050267018-A1 | Macrocyclic compounds as inhibitors of viral replication | HOFFMANN-LA ROCHE INC. | 2005-12-01 | — | — | US | disclosed |
| WO-2005095403-A2 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. (US) | 2005-10-13 | — | — | WO | disclosed |
| WO-2005037214-A2 | MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULFONAMIDES AS INHIBITORS OF HCV REPLICATION | INTERMUNE, INC. (US) | 2005-04-28 | — | — | WO | disclosed |
| EP-0321191-B1 | Heterocyclic-substituted quinoline-carboxylic acids | PFIZER (US) | 1994-11-02 | — | — | EP | disclosed |
| US-5214051-A | Thiazolyl and oxazolyl[5,4-c]piperidyl-substituted quinolone-carboxylic acid and related analogs thereof having antibacterial properties are disclosed | PFIZER INC. (US) | 1993-05-25 | — | — | US | disclosed |
| US-5037834-A | Heterocycylic-substituted quinoline-carboxylic acids | PFIZER INC. (US) | 1991-08-06 | — | — | US | disclosed |
| WO-1989005643-A1 | HETEROCYCLIC-SUBSTITUTED QUINOLINE-CARBOXYLIC ACIDS | PFIZER INC. (US) | 1989-06-29 | — | — | WO | disclosed |
| EP-0321191-A2 | Heterocyclic-substituted quinoline-carboxylic acids | PFIZER INC. (US) | 1989-06-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267018-A1 | Macrocyclic compounds as inhibitors of viral replication | EIF2AK2, HAVCR2, ZC3HAV1 | PDCD1 3090/4885CD274 3566/4885PNMT 2339/4885 |
| US-20240368188-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM4, CHRM5, CHRM1 | PDCD1 3920/4885CD274 2679/4885PNMT 76/4885 |
| US-12139498-B1 | Positive allosteric modulators of the muscarinic acetylcholine receptor M4 | CHRM4, CHRM5, CHRM1 | PDCD1 3866/4885CD274 2658/4885PNMT 75/4885 |
| US-20230052191-A1 | NOVEL COMPOUNDS | UCHL1, UCHL3, UCHL5 | PDCD1 855/4885CD274 1059/4885PNMT 4019/4885 |
| US-20230218597-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | ALK, ACVR1, ACVR2A | PDCD1 3348/4885CD274 3380/4885PNMT 3139/4885 |
| US-11590116-B2 | Substituted pyridines and methods of use | ALK, ACVR1, ACVR2A | PDCD1 3348/4885CD274 3380/4885PNMT 3139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.